Glancy Prongay & Murray LLP Commences Investigation on Behalf of United Therapeutics Corporation Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of United Therapeutics Corporation
(“United Therapeutics” or the “Company”) (NASDAQ: UTHR) investors concerning the Company and its officers’ possible violations of federal securities laws. To
obtain information or aid in the investigation, please visit the United Therapeutics investigation page on our website at http://www.glancylaw.com/case/united-therapeutics-corporation.
On July 27, 2017, the Company disclosed that it recorded a $210 million accrual relating to a potential settlement in connection
with a DOJ investigation into the Company’s possible violations of the Federal Anti-Kickback Statute and the Federal False Claims
Act. On this news, the Company’s stock price fell approximately 5% during intraday trading on July 27, 2017.
If you purchased United Therapeutics securities, have information or would like to learn more about these claims, or have any
questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006416/en/